$3.055
+0.119 (+3.91%)收盘时
PBM 同业对比
In the context of the broader market, PBM competes directly with industry leaders such as IMRN and PTN. With a market capitalization of $11.64M, it holds a leading position in the sector. When comparing efficiency, PBM's gross margin of N/A stands against IMRN's 63.42% and PTN's 100.00%. Such benchmarking helps identify whether Psyence Biomedical Ltd is trading at a premium or discount relative to its financial performance.
Psyence Biomedical Ltd 财务表现
The financial performance shows a net income of 141,473 USD in Q3 2025, but a significant loss of -753,254 USD in Q2 2026. The current ratio is 8.09, indicating good short-term liquidity, but the debt-to-equity ratio is concerning at -199.26% in Q3 2025, suggesting financial instability.
Financials
相关文章
- CPI Report and the Stock Market: How to Read October 2026 Inflation Data Before the Fed DecidesOctober 2026 CPI lands Nov 10 with no year-over-year number and Fed hike odds near 80%. Learn how to read CPI, which stocks react, and how to plan for it.
- Are You Buying NVIDIA’s Earnings or Its CEO’s Perfect Image?An Alphio analysis of NVIDIA’s share-price timeline, operating results, governance uncertainty and upcoming earnings.
- Stock Market After the 2026 Midterms: What a Democratic Congress Means for InvestorsDemocrats swept Congress in the 2026 midterms. See how stocks reacted, what history says about post-midterm returns, and which sectors face new risks.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。